

**FIRST SUPPLEMENT DATED 23 SEPTEMBER 2022 TO THE BASE PROSPECTUS  
DATED 13 JULY 2022**



**EMIRATES NBD BANK PJSC**

*(incorporated with limited liability in the United Arab Emirates)*

**U.S.\$20,000,000,000**

**Euro Medium Term Note Programme**

This supplement (the "**Supplement**") is supplemental to, forms part of and must be read and construed in conjunction with, the base prospectus dated 13 July 2022 (together, the "**Base Prospectus**") prepared by Emirates NBD Bank PJSC ("**ENBD**" or the "**Issuer**") in connection with its Euro Medium Term Note Programme (the "**Programme**") for the issuance of up to U.S.\$20,000,000,000 in aggregate principal amount of notes ("**Notes**"). Terms given a defined meaning in the Base Prospectus shall, unless the context otherwise requires, have the same meaning when used in this Supplement.

This Supplement has been approved by the Central Bank of Ireland (the "**CBI**") as competent authority under Regulation (EU) 2017/1129 (the "**Prospectus Regulation**"), as a base prospectus supplement issued in compliance with the Prospectus Regulation. The CBI only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer or of the quality of the Notes that are the subject of the Base Prospectus.

This Supplement complies with the requirements of Part 2 of the Markets Law (DIFC Law No. 1 of 2012) (the "**Markets Law**") and Chapter 2 of the Markets Rules (the "**Markets Rules**"). This Supplement has been approved by the Dubai Financial Services Authority (the "**DFSA**") under Rule 2.6 of the Markets Rules and is an Approved Prospectus for the purposes of Article 14 of the Markets Law. The DFSA does not accept any responsibility for the content of the information included in this Supplement, including the accuracy or completeness of such information. The liability for the content of this Supplement lies with the Issuer. The DFSA has also not assessed the suitability of the Notes to which this Supplement relates to any particular investor or type of investor.

If you do not understand the contents of this Supplement or are unsure whether the Notes to which this Supplement relates are suitable for your individual investment objectives and circumstances, you should consult an authorised financial advisor.

The purpose of this Supplement is to: (i) incorporate by reference into the Base Prospectus the unaudited condensed consolidated interim financial statements of ENBD as at and for the six months ended 30 June 2022 and the independent auditors' review report thereon; and (ii) update the "Significant or Material Change" statement accordingly.

## IMPORTANT NOTICES

ENBD accepts responsibility for the information contained in this Supplement. To the best of the knowledge of ENBD, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Information which is updated by reference to one section of the Base Prospectus may be repeated or referred to in other sections of that document. Accordingly, to the extent that there is any inconsistency between: (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement; and (b) any other statement in, or incorporated by reference into, the Base Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement, no significant new factor, material mistake or material inaccuracy relating to the information included in the Base Prospectus which is capable of affecting the assessment of any Notes issued under the Programme has arisen or been noted, as the case may be, since the publication of the Base Prospectus.

Copies of this Supplement and the Base Prospectus are available for viewing on the website of the Irish Stock Exchange plc trading as Euronext Dublin at <https://live.euronext.com>, the website of Nasdaq Dubai at <http://www.nasdaqdubai.com> and during normal business hours from the registered office of ENBD at Baniyas Road, Deira, P.O. Box 777, Dubai, UAE and the specified office of the Principal Paying Agent at Winchester House, 1 Great Winchester Street, London EC2N 2DB.

This Supplement does not constitute an offer to sell or the solicitation of an offer to buy any Notes in any jurisdiction to any person to whom it is unlawful to make the offer or solicitation in such jurisdiction.

The Notes have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**") and Notes in bearer form are subject to U.S. tax law requirements. Subject to certain exceptions, Notes may not be offered, sold or delivered within the United States or to, or for the account or benefit of, U.S. persons (see "*Subscription and Sale*" in the Base Prospectus).

## AMENDMENTS OR ADDITIONS TO THE BASE PROSPECTUS

With effect from the date of this Supplement, the information appearing in, or incorporated by reference into, the Base Prospectus shall be amended and/or supplemented in the manner described below.

### 1. Incorporation of ENBD's Q2 2022 Financial Statements

On 28 July 2022, ENBD published its unaudited condensed consolidated interim financial statements as at and for the six months ended 30 June 2022 together with the independent auditors' review report thereon (the "**Q2 2022 Financial Statements**").

A copy of the Q2 2022 Financial Statements has been filed with the CBI and the DFSA. The Q2 2022 Financial Statements are incorporated by reference in, and form part of, this Supplement in their entirety and, by virtue of this Supplement, form part of the Base Prospectus.

Copies of the Q2 2022 Financial Statements can be obtained from the website of the Irish Stock Exchange plc trading as Euronext Dublin (<https://live.euronext.com/>) and, upon request, free of charge from: (a) the registered office of ENBD at Baniyas Road, Deira, P.O. Box 777, Dubai, UAE and the specified office of the Principal Paying Agent at Winchester House, 1 Great Winchester Street, London EC2N 2DB; and (b) ENBD's website at:

[https://www.emiratesnbd.com/plugins/FinanceManagement/QuarterlyReports/FinanciaIEng/Emirates\\_NBD\\_Financial\\_Statements\\_H1\\_2022\\_English.pdf](https://www.emiratesnbd.com/plugins/FinanceManagement/QuarterlyReports/FinanciaIEng/Emirates_NBD_Financial_Statements_H1_2022_English.pdf)

Unless specifically incorporated by reference into this Supplement or the Base Prospectus, the information contained on ENBD's website is not incorporated by reference into, or otherwise included in, this Supplement or the Base Prospectus.

For the avoidance of doubt, any documents incorporated by reference in the Q2 2022 Financial Statements shall not form part of this Supplement or the Base Prospectus.

### 2. Amendments to the Base Prospectus

2.1 The following paragraph shall be deemed to be added as new paragraph (i) under the section headed "*Documents Incorporated by Reference*" on page 33 of the Base Prospectus (and the numbering of the subsequent paragraphs shall be deemed to be amended accordingly):

- "(a) the unaudited condensed consolidated interim financial statements of ENBD as at and for the six months ended 30 June 2022, including:
- (i) consolidated interim statement of financial position (page 2);
  - (ii) consolidated interim income statement (page 3);
  - (iii) consolidated interim statement of comprehensive income (page 4);
  - (iv) consolidated interim statement of cash flows (page 5);

- (v) consolidated interim statement of changes in equity (page 6);
- (vi) notes to the consolidated interim financial statements (pages 7-32); and
- (vii) independent auditors' review report (page 1)".

2.2 The paragraph under the heading "*Significant or Material Change*" on page 172 of the Base Prospectus shall be deleted in its entirety and replaced with the following:

"There has been no significant change in the financial or trading position or financial performance of the Group since 30 June 2022 and there has been no material adverse change in the prospects of the Issuer since 31 December 2021."